Table 4 Novel PH agents are being tested
From: Novel insights and new therapeutic potentials for macrophages in pulmonary hypertension
Agent | Function | Phase | Classification | Study ID and registration date |
|---|---|---|---|---|
LAM-001 | mTOR inhibitor | Phase 2 | Group-1 or -3 | NCT05798923 (April 5, 2023) |
Metformin | AMPK activator | Phase 2 | Group 2 | NCT03629340 (August 14, 2018) |
AZD3427 | relaxin mimetic agonist | Phase 2 | Group 2 | NCT05737940 (February 21, 2023) |
MK-5475 | sGC stimulator | Phase 2 | Group-3 | NCT05612035 (November 10, 2022) |
Dapagliflozin | SGLT2 inhibitor | Phase 2 | Group-1 or -4 | NCT05179356 (January 5, 2022) |
LTP001 | SMURF1 antagonists | Phase 2 | Group-1 | NCT05135000 (November 26, 2021) |
Sotatercept | activin signalling inhibitor | Phase 2, 3 | Group-1 or -2 | NCT04945460 (June 30, 2021), NCT04896008 (May 21, 2021), NCT04811092 (March 23, 2021), NCT05587712 (October 20, 2022), NCT04796337 (March 12, 2021) |
KER-012 | TGF-β inhibitor | Phase 2 | Group-1 | NCT05975905 (August 4, 2023) |
iMatinib | tyrosine kinase inhibitor | Phase 3 | Group-1 | NCT05557942 (September 28, 2022) |
Seralutinib | PDGFRα and PDGFRβ inhibitor | Phase 2, 3 | Group-1 | NCT04816604 (March 25, 2021), NCT05934526 (July 7, 2023) |
Ralinepag | prostacyclin receptor agonist | Phase 3 | Group-1 | NCT03683186 (September 25, 2018), NCT03626688 (August 13, 2018) |
ZMA001 | Lysyl-tRNA synthetase inhibitor | Phase 1 | Healthy volunteers | NCT05967299 (August 1, 2023) |